Clinical Genomics Scientist, Oncology

Remote

Auto‑apply with AI Apply

Not SpecifiedCompensation

Junior (1 to 2 years)Experience Level

Full TimeJob Type

UnknownVisa

Healthcare, Biotechnology, Medical DiagnosticsIndustries

Requirements

Candidates must hold a Ph.D. in Human Genetics, an M.S. in Genetic Counseling, or a related field, and possess at least two years of experience in somatic variant interpretation based on ACMG/AMP guidelines within a clinical setting, or alternatively, one year of germline variant interpretation combined with one year of somatic variant interpretation.

Responsibilities

The Clinical Genomics Scientist, Oncology will perform somatic-based variant interpretation, classifying variants and matching treatments for reporting, verifying data with BAM file analysis; draft clinical reports primarily using an in-house reporting API, collaborating with engineering and QA teams and laboratory directors on report language; develop and modify somatic interpretation SOPs in accordance with ACMG/AMP guidelines and the latest published literature; contribute to curation of gene-level content; serve as a subject matter expert in molecular tumor boards, consulting with the medical science liaison team; and contribute to oncology R&D projects, providing expertise on variant interpretation, biological pathways, and gene/variant-level reviews and analyses.

Skills

Somatic mutation interpretation

Variant analysis

Report drafting

Guideline development

Liquid biopsy

Cancer genomics

Molecular diagnostics

BillionToOne

Molecular diagnostics for prenatal and oncology testing

About BillionToOne

BillionToOne specializes in molecular diagnostics within the healthcare sector, focusing on prenatal screening and oncology testing. Their proprietary QCT technology allows for the detection and quantification of diseases at a single base-pair resolution, enabling the identification of minute variations in DNA. The company offers two main products: Northstar Select™, which helps determine the best initial therapy for patients, and Northstar Response™, which tracks the effectiveness of that therapy. Unlike many competitors, BillionToOne emphasizes accuracy, efficiency, and accessibility in molecular testing, providing diagnostic services directly to healthcare providers. Their goal is to positively impact healthcare by making molecular testing more reliable and available to everyone.

Menlo Park, CaliforniaHeadquarters

2016Year Founded

$380.2MTotal Funding

SERIES_DCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Competitive pay

Retirement savings package

Parental leave

Free snacks & lunches

Medical, dental, & vision premiums

On campus perks

Free-on-site EV charging

Risks

Emerging biotech startups could threaten BillionToOne's market share.

Rapid technological advancements may render their current technology obsolete.

Expansion into new facilities may face operational challenges or delays.

Differentiation

BillionToOne's QCT technology detects DNA variations at single base-pair resolution.

Their UNITY Fetal Antigen NIPT is the first US cfDNA test for fetal antigen genotyping.

They replace invasive amniocentesis with a safe, affordable blood test for prenatal screening.

Upsides

BillionToOne achieved a billion-dollar valuation with a $130 million funding round.

Their new Austin facility will create 1,000 jobs, boosting production and local economy.

Recognition as Diagnostics Company of the Year highlights their industry leadership.

Land your dream remote job 3x faster with AI

Try Jobo Free